Literature DB >> 23344123

Incidence of postoperative residual neuromuscular blockade in the postanaesthesia care unit: an observational multicentre study in Portugal.

Simão Esteves1, Mafalda Martins, Filinto Barros, Fernanda Barros, Manuela Canas, Paula Vitor, Manuel Seabra, Maria M Castro, Isabel Bastardo.   

Abstract

CONTEXT: Residual neuromuscular blockade still presents despite the use of intermediate duration muscle relaxants and is a risk factor for postoperative morbidity.
OBJECTIVE: To determine the incidence of incomplete postoperative neuromuscular recovery from anaesthesia in a postanaesthesia care unit.
DESIGN: Multicentre observational study.
SETTING: Public Portuguese hospitals. PATIENTS: Adult patients scheduled for elective surgery requiring general anaesthesia with neuromuscular blocking agents. MAIN OUTCOME MEASURES: An independent anaesthesiologist measured neuromuscular transmission by the TOF-Watch SX acceleromyograph. Train-of-four ratios at least 0.9 and less than 0.9 were assessed as complete and incomplete neuromuscular recovery following general anaesthesia, respectively.
RESULTS: The study population consisted of 350 patients [134 men and 216 women, mean (SD) age 54.3 (15.9) years]. Ninety-one patients had a train-of-four ratio less than 0.9 on arrival in the postanaesthesia care unit, an incidence of residual neuromuscular blockade of 26% [95% confidence interval (CI) 21 to 31%]. The most frequent neuromuscular blockers were rocuronium (44.2%) and cisatracurium (32%). A neuromuscular block reversal agent was used in 66.6% of the patients (neostigmine in 97%). The incidence of residual neuromuscular blockade in patients receiving reversal agents was 30% (95% CI 25 to 37%). There were no statistically significant differences in the occurrence of residual blockade relating to the neuromuscular blocker used, although higher percentages were observed for cisatracurium (32.4%) and vecuronium (32%) compared with atracurium (23.6%) and rocuronium (20.8%). Incomplete neuromuscular recovery was significantly more frequent among patients who had received a reversal agent (30.5 vs. 17.1%, P = 0.01). Incomplete neuromuscular recovery was more frequent in patients given propofol than in those exposed to sevoflurane (26.2 vs. 14.3%).
CONCLUSION: The incidence of incomplete neuromuscular recovery of 26% confirms that it is relatively frequent in the postoperative period and calls attention to the dimension of this problem in Portugal.

Entities:  

Mesh:

Year:  2013        PMID: 23344123     DOI: 10.1097/EJA.0b013e32835dccd7

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  6 in total

1.  A survey of the current use of neuromuscular blocking drugs among the Middle Eastern anesthesiologists.

Authors:  Abdelazeem Eldawlatly; Mohamed R El-Tahan
Journal:  Saudi J Anaesth       Date:  2013-04

2.  Use of neuromuscular blockers and neostigmine for general anesthesia and its association with neuraxial blockade: A retrospective study.

Authors:  Filipe Nadir Caparica Santos; Angélica de Fátima de Assunção Braga; Fernando Eduardo Feres Junqueira; Rafaela Menezes Bezerra; Felipe Ferreira de Almeida; Franklin Sarmento da Silva Braga; Vanessa Henriques Carvalho
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

3.  Usefulness of intra-operative neuromuscular blockade monitoring and reversal agents for postoperative residual neuromuscular blockade: a retrospective observational study.

Authors:  Gonzalo Domenech; Matías A Kampel; María E García Guzzo; Delfina Sánchez Novas; Sergio A Terrasa; Gustavo Garcia Fornari
Journal:  BMC Anesthesiol       Date:  2019-08-07       Impact factor: 2.217

4.  A multicenter survey on the use of neuromuscular blockade in Greece. Does the real-world clinical practice indicate the necessity of guidelines?

Authors:  Chrysanthi Batistaki; Kyriaki Vagdatli; Adelais Tsiotou; Alexandra Papaioannou; Aggeliki Pandazi; Paraskevi Matsota
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2019 Apr-Jun

5.  Economic impact of improving patient safety using Sugammadex for routine reversal of neuromuscular blockade in Spain.

Authors:  J Martinez-Ubieto; C Aragón-Benedí; J de Pedro; L Cea-Calvo; A Morell; Y Jiang; S Cedillo; P Ramírez-Boix; A M Pascual-Bellosta
Journal:  BMC Anesthesiol       Date:  2021-02-16       Impact factor: 2.217

6.  Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center.

Authors:  Michele Carron; Fabio Baratto; Francesco Zarantonello; Carlo Ori
Journal:  Clinicoecon Outcomes Res       Date:  2016-02-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.